Physician profile
Mary Cutting
NPI 1851491831
$1,471.25
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $574.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $513.51 | 2019-2020 | |
| Therapeuticsmd, INC. | $308.33 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $152.93 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $120.29 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.62 | 2019-2020 | |
| Lupin INC. | $72.21 | 2020 | |
| Exeltis, USA INC. | $67.24 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $62.19 | 2019-2020 | |
| Pfizer INC. | $42.76 | 2020 | |
| Roche Diagnostics Corporation | $19.46 | 2019 | |
| Allergan, INC. | $18.86 | 2020 | |
| Avion Pharmaceuticals | $11.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Cutting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.